mRNA Technology Expands to Cancer Vaccines: Personalized Tumor Vaccines Enter Clinical Trials

Moderna and BioNTech announce mRNA technology for personalized cancer vaccines. First 1,000 patients participate in clinical trials. Data shows tumor shrinkage rate of 60%.

mRNA technology leaders Moderna and BioNTech simultaneously release cancer vaccine clinical data.

Clinical Data

Participating patients: 1,000
Tumor shrinkage rate: 60%
Complete remission rate: 15%
Median survival extension: 8 months

Technology

Personalized mRNA cancer vaccine:

Surgical tumor tissue removal
AI analysis of mutation characteristics
Customized mRNA vaccine
Regular vaccination treatment

Pricing

Expected at $100,000-$300,000 per dose, not yet on market.

Timeline

2028: Apply for FDA Breakthrough Therapy designation
2030: Expected to receive approval for market

Disclaimer

Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.